VYNE Therapeutics Inc. — Director's Dealing 2021

Dec 2, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VYNE Therapeutics Inc. (VYNE)
CIK: 0001566044
Period of Report: 2021-11-30

Reporting Person: LEPORE PATRICK G (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-11-30	Common Stock	P	12500	$1.0159	Acquired	62500	Direct

Footnotes

F1: Shares were purchased pursuant to a 10b5-1 plan entered into by the reporting person on April 21, 2021.

F2: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.98 to $1.03, inclusive. The reporting person undertakes to provide to VYNE Therapeutics Inc., any security holder of VYNE Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.